Skip to content

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00853580
Acronym
STARS
Enrollment
146
Registered
2009-03-02
Start date
2009-07-31
Completion date
2016-12-31
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurofibromatosis Type 1

Keywords

Neurofibromatosis Type 1, Neurocognitive, Phase II

Brief summary

The specific aim of this study is to determine whether Lovastatin ™ significantly improves visual spatial learning and/or sustained attention in children with NF1. Secondary Aims: To evaluate the effect of Lovastatin ™ on measures of executive function, behavior and quality of life in children with NF1 and cognitive deficits. To further evaluate the toxicity and tolerability of Lovastatin ™ in children with NF1 and cognitive deficits. Hypotheses It is hypothesized that Lovastatin ™ will improve the visual spatial memory and/or attention deficits in children with NF1. This is based on studies demonstrating that Lovastatin ™ has significantly improved impairments in visual spatial memory and attention in the NF1 murine model. It is further expected that Lovastatin ™ will be safe and well tolerated over a 16-week period.

Detailed description

Study Design This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo. It is plausible and ethical to employ a placebo group as no standard therapy with established efficacy is being withheld. There is no cross-over in this study due to a lack of data concerning the length of possible washout effects. The Lovastatin ™ dose will begin at 20 mg once daily/continuous dosing and escalate over a two-week period to 40 mg once daily/continuous dosing and continue at this dose for 14 weeks. Participants will be carefully monitored for side effects. The safety of Lovastatin ™ will be evaluated using laboratory tests, clinical signs and adverse effects, which will be monitored at regular intervals over the 16-week period. Primary and secondary outcome measures will be administered at baseline, 16 weeks post-treatment and at follow-up, 8 weeks after cessation of treatment to determine any carry-over effects. The safety of Lovastatin ™ will also be evaluated, with regular monitoring of side-effects during the trial. Study Population This is a Phase II study involving children with NF1 (aged between 8 years to 15 years 11 months old at time of enrollment) with evidence of cognitive impairment, defined as having a score of at least one standard deviation or more below the population mean on a measure of visual spatial learning and/or attention. A total of 142 participants with NF1 aged between 8 years and 15 years 11 months will be enrolled in the study. The age limits were selected on the basis that Lovastatin ™ has been shown to be safe in children aged between 8 and 17 years old. In addition, one of the primary outcome measures (attention) only has normative data for up to 15 years 11 months. Therefore, the maximum age limit for participants at time of enrolment is 15 years 11 months so that normative data can be used to determine whether participants are impaired. The pediatric NF1 population is an ideal group in which to study the cognitive effects of Lovastatin ™ because it represents an opportunity for early pharmacological intervention of cognitive deficits.

Interventions

DRUGLovastatin ™

Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.

DEVICEplacebo

Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.

Sponsors

Boston Children's Hospital
CollaboratorOTHER
Children's Hospital of Philadelphia
CollaboratorOTHER
Children's National Research Institute
CollaboratorOTHER
Children's Hospital Medical Center, Cincinnati
CollaboratorOTHER
National Cancer Institute (NCI)
CollaboratorNIH
University of Chicago
CollaboratorOTHER
University of Utah
CollaboratorOTHER
Washington University School of Medicine
CollaboratorOTHER
Sydney Children's Hospitals Network
CollaboratorOTHER
University of Texas Southwestern Medical Center
CollaboratorOTHER
University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
8 Years to 15 Years
Healthy volunteers
Yes

Inclusion criteria

* Males or females aged between 8 years and 15 years 11 months at time of enrollment who meet NIH diagnostic criteria for NF1 (Appendix 1) * Participants must have a full-scale IQ of 70 or above. In cases where there is a statistically significant difference between verbal IQ and performance IQ (.05 level as determined by Table B3 in the WASI manual), participants will be eligible if at least one of these quotients is 70 or above * Participants must have a cognitive impairment defined as having a score of at least one standard deviation or more below the population mean on one or more of the primary objective outcome measures (i.e., impaired on a measure of visual spatial learning and/or sustained attention) * Participants must be medically stable * Participants who are on a stable dose of methylphenidate and/or dextroamphetamines for at least one month prior to screening and who will remain on the same dose for the duration of the study. * Hepatic function: Participants must have a bilirubin within normal limits and AST and ALT ± 2 times the upper limit of normal as determined by the standards at their institution * Renal function: Participants must have an age-adjusted normal serum creatinine or a creatinine clearance of greater than 70 ml/m/1.73m2 * Hematologic function: Participants must have an absolute neutrophil count of greater than 1,500, a hemoglobin of greater than 9 gms/dl, and a platelet count of greater than 100,000 on study entry * Participants must sign all required documents, including informed assent and HIPAA documents * Female participants of childbearing age should not be pregnant, must have a negative pregnancy test before initiation of treatment, and take appropriate birth control precautions to participate in this study.

Exclusion criteria

* Full-scale IQ less than 70; In cases where this is a statistically significant difference between performance IQ and verbal IQ (.05 level), patients will be excluded if both quotients fall below 70 * Individuals that are not cognitively impaired on at least one of the primary objective outcome measures * Individuals with insufficient English to complete the assessments * Participants taking psychotropic medication other than methylphenidate and/or dextroamphetamines. These patients are eligible if, as clinically indicated, they cease medication for at least 30 days prior to screening and remain off these medication for the duration of the study * Participants with intracranial pathology such as epilepsy, diagnosed head injury, hydrocephalus or progressive intracranial tumors (children with asymptomatic or static lesions will be eligible) * Participants who are pregnant or breastfeeding; Participants who have received any investigational drug, other than sirolimus, within 30 days of initiation of study * Participants who have recently taken Lovastatin. These participants will be eligible after a washout period of at least three months. * Participants with significant hepatic, renal or hematologic function as previously defined * Participants with a history of neuromuscular disease, excluding hypotonias thought to be associated with NF1 * Participants with a clinically significant unrelated illness, which in the judgment of the principal or associate investigator, would compromise the participant's ability to tolerate the medication or potentially interfere with the participant's ability to participate in the required testing * Low cholesterol (lower limit of a total cholesterol of 90mg/dl) * Participants who have recently taken sirolimus within three months of enrollment. These participants will be eligible after a washout period of at least three months.

Design outcomes

Primary

MeasureTime frameDescription
Paired Associate Learning (Cambridge Neuropsychological Test Automated Battery).Baseline and Post-treatment (16 weeks)A computerized test of visuospatial learning. Participants had to remember patterns associated with different locations on the screen, and during the test phase, as each pattern is presented, point to the appropriate location. The test starts at a very simple level and gradually increases in difficulty. Higher number of errors indicates poorer performance. Scale does not have a maximum range.
Score! (Test of Everyday Attention for Children)Baseline and Post-treatment (16 weeks)Score! is a measure of sustained attention. Participants were required to silently count a series of aurally presented tones and say the total number of tones counted at the end of each trial. The number of tones ranged from 9 to 15, with a total of 10 trials (range 0-10). Higher values represent better performance.

Secondary

MeasureTime frameDescription
Stop Signal Task (Cambridge Neuropsychological Test Automated Battery)Baseline and Post-treatment (16 weeks)A computerized measure of inhibitory control. The participant quickly responded to an arrow stimulus by pressing one of two buttons (left or right), depending on the direction in which the arrow pointed on the screen. If an audio tone is present, the subject was supposed to withhold the response. The difficulty of the task was manipulated by altering the delay before a stop signal (auditory tone) was presented, known as the stop signal delay. The outcome from this measure was stop signal reaction time (last half of test), which was computed by subtracting the mean stop signal delay at which the participant was able to stop on 50% of trials from the mean reaction time on go trials. Poorer response inhibition was reflected by a larger stop signal reaction time. Scale does not have a maximum range.
Sky Search (Test of Everyday Attention for Children)Baseline and Post-treatment (16 weeks)Sky Search is a measure of selective visual attention. Participants were presented with a A3 sheet with target stimuli (spaceships in identical pairs) randomly distributed among many distractors (spaceships in non-identical pairs). They were required to circle as many of the targets as possible as quickly as possible. The outcome measure (attention score), was a timing score reflecting the average time taken per target found. Higher scores represent poorer performance. Raw data are reported. Scale does not have a maximum range.
Sky Search DT (Test of Everyday Attention for Children)Baseline and Post-treatment (16 weeks)Sky Search DT is a test of divided attention. Children completed a parallel version of the Sky Search subtest while at the same time, silently counted the number of tones in a similar way to the Score! subtest. Higher scores represent poorer performance. Raw data are reported. Scale does not have a maximum range.
Creature Counting (Test of Everyday Attention for Children)Baseline and Post-treatment (16 weeks)Creature Counting is a measure of attentional control. Participants were required to count creatures from top of the page to the bottom, using arrows as cues to switch from counting up to counting down (and vice versa). There were seven testing trials. The outcome variable was the total number of correct trials (range 0-7). Higher scores represent better performances.
Commission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Baseline and Post-treatment (16 weeks)A computerised measure of impulse control. Letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Commission errors represented the number of times a participant incorrectly responded to the non-target (letter 'X'). T-scores are reported, as generated by the test software. Higher scores indicate poorer performances.
Omission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Baseline and Post-treatment (16 weeks)A computerised measure of vigilance and concentration. Letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Omission errors represented the number of times a participant fails to respond to target letters (all other than 'X'). T-scores are reported, as generated by the test software. Higher scores indicate poorer performances.
ADHD Inattentive Scale, Conners ADHD ScalesBaseline and Post-treatment (16 weeks)Parent rated inattentive ADHD symptoms, based on Diagnostic and Statistical Manual of Mental Disorders criteria, 4th edition. T-scores are reported. Higher scores indicate increased ADHD-related symptoms. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.
Spatial Working Memory (Cambridge Neuropsychological Test Automated Battery)Baseline and Post-treatment (16 weeks)A computerized measure of spatial working memory. This task assessed the participant's ability to retain spatial information and to manipulate remembered items in working memory. In this test, participants were shown an array of boxes on a computer screen and they were required to search through the boxes for hidden tokens. One box at a time was touched until a blue token was found inside. Participants then commenced a new search for the next token. The key instruction was that, once a token had been located, that box would not be used again to hide another token. Unit of measure was between search errors, determined by the number of boxes a participant reopens in which a token had previously been found. Higher score indicated poorer performance. Scale does not have a maximum range.
Controlled Oral Word Association TestBaseline and Post-treatment (week 16)A measure of verbal fluency. Participants were required to spontaneously produce as many words as they could, beginning with a designated letter in 60 seconds. Three letters were used. Higher scores represent better performances. Raw data are reported summing total words generated for all three letters. Scale does not have a maximum range.
Judgement of Line Orientation TestBaseline and Post-treatment (week 16)A test of visuospatial judgement. The test measured the participant's ability to match the angle and orientation of lines in space. There were 30 trial in total. Correct response in a trial was awarded one point (range 0-30). Higher scores represent better performances. Raw data are reported.
Behavior Rating Inventory of Executive Function Global Executive CompositeBaseline and Post-treatment (week 16)A parent-rated questionnaire of executive behaviour assessing behavioral regulation (inhibit, shift, emotional control) and metacognition (initiate, working memory, plan/organize, organization of materials, self-monitoring). T-scores for the Global Executive Composite (overall summary score) are reported. Higher scores indicate poorer executive behaviors.
Object Assembly (WISC-III)Baseline and Post-treatment (week 16)A measure of visuoperceptual organization. Participants were required to rebuild an item puzzle based on disassembled pieces. Age scaled scores are reported, which have a population mean of 10 and standard deviation of 3 (range 1-19). Higher scores indicate better performances.
Internalizing Behaviors, Behavior Assessment System for Children Second EditionBaseline and Post-treatment (week 16)A parent-reported questionnaire assessing internalizing behaviors of anxiety, depression and somatization. T-scores are reported. Higher scores indicate increased internalizing behaviors. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.
Quality of Life Pediatric Quality of Life Inventory (PedsQL)Baseline and Post-treatment (week 16)Parent-rated questionnaire of psychosocial Quality of Life (including emotional, social and school functioning). Summary scores are reported. Higher scores indicate increased increased quality of life (range 0-100).
Psychosocial Quality of Life PedsQLBaseline and Post-treatment (week 16)Self-rated questionnaire of psychosocial Quality of Life (including emotional, social and school functioning). Summary scores are reported. Higher scores indicate higher quality of life (range 0-100).
ADHD Hyperactive/Impulsive Scale, Conners ADHD ScalesBaseline and Post-treatment (16 weeks)Parent rated hyperactive/impulsive ADHD symptoms, based on Diagnostic and Statistical Manual of Mental Disorders criteria, 4th edition.T-scores are reported. Higher scores indicate increased ADHD-related symptoms. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.
Stockings of Cambridge (Cambridge Neuropsychological Test Automated Battery) Automated Battery).Baseline and Post-treatment (16 weeks)A computerized measure of spatial planning based on the Tower of London test. It required participants to move balls in a lower display to match a pattern shown in the upper display in a certain number of moves. More specifically, the participant was shown two displays containing three coloured balls. The displays were presented in such a way that they could be perceived as stacks of coloured balls held in socks suspended from a beam. The test administrator first demonstrated to the participant how to move the balls in the lower display to copy the pattern in the upper display and completed one demonstration problem, where the solution required one move. The participant then completed problems that increased in difficulty, from one through to five move problems. The unit of measure was the mean number of moves taken to complete a problem that could not be completed in less than five moves. The higher the score, the poorer the performance (range 5-12).

Countries

Australia, United States

Participant flow

Recruitment details

Participants were recruited between July 2009 and May 2014 from 11 specialist NF1 academic clinics affiliated with the NF Clinical Trials Consortium.

Pre-assignment details

After obtaining consent, participants were screened for study inclusion. If entry criteria were passed, they were randomized to study. All randomized participants were included in the primary efficacy analysis (baseline-to-post treatment) if they completed the baseline assessments.

Participants by arm

ArmCount
Lovastatin
Oral lovastatin contained within in opaque capsules at a dose of 20mg a day (2 weeks) increased to a fixed dose of 40mg a day (14 weeks).
74
Placebo
Look alike placebo capsule with same dosing schedule as active lovastatin.
70
Total144

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyCommenced contraindicated therapy02
Overall StudyLost to Follow-up35
Overall StudyProtocol Violation21
Overall StudyWithdrawal by Subject28

Baseline characteristics

CharacteristicLovastatinPlaceboTotal
Age, Categorical
<=18 years
74 Participants70 Participants144 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous11.5 Years
STANDARD_DEVIATION 2.25
11.7 Years
STANDARD_DEVIATION 1.95
11.6 Years
STANDARD_DEVIATION 2.1
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
6 Participants11 Participants17 Participants
Race (NIH/OMB)
More than one race
7 Participants5 Participants12 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
61 Participants54 Participants115 Participants
Region of Enrollment
Australia
17 participants17 participants34 participants
Region of Enrollment
United States
57 participants55 participants112 participants
Sex: Female, Male
Female
31 Participants27 Participants58 Participants
Sex: Female, Male
Male
43 Participants43 Participants86 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 740 / 70
other
Total, other adverse events
65 / 7459 / 70
serious
Total, serious adverse events
6 / 741 / 70

Outcome results

Primary

Paired Associate Learning (Cambridge Neuropsychological Test Automated Battery).

A computerized test of visuospatial learning. Participants had to remember patterns associated with different locations on the screen, and during the test phase, as each pattern is presented, point to the appropriate location. The test starts at a very simple level and gradually increases in difficulty. Higher number of errors indicates poorer performance. Scale does not have a maximum range.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinPaired Associate Learning (Cambridge Neuropsychological Test Automated Battery).Baseline15.8 PAL Total ErrorsStandard Error 22.4
LovastatinPaired Associate Learning (Cambridge Neuropsychological Test Automated Battery).Post-treatment10.3 PAL Total ErrorsStandard Error 8.4
PlaceboPaired Associate Learning (Cambridge Neuropsychological Test Automated Battery).Baseline17.0 PAL Total ErrorsStandard Error 15.4
PlaceboPaired Associate Learning (Cambridge Neuropsychological Test Automated Battery).Post-treatment11.7 PAL Total ErrorsStandard Error 11.7
p-value: 0.51ANCOVA
Primary

Score! (Test of Everyday Attention for Children)

Score! is a measure of sustained attention. Participants were required to silently count a series of aurally presented tones and say the total number of tones counted at the end of each trial. The number of tones ranged from 9 to 15, with a total of 10 trials (range 0-10). Higher values represent better performance.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinScore! (Test of Everyday Attention for Children)Baseline6.0 Units on a scaleStandard Deviation 2
LovastatinScore! (Test of Everyday Attention for Children)Post-treatment7.3 Units on a scaleStandard Deviation 2.1
PlaceboScore! (Test of Everyday Attention for Children)Baseline5.7 Units on a scaleStandard Deviation 2.4
PlaceboScore! (Test of Everyday Attention for Children)Post-treatment6.8 Units on a scaleStandard Deviation 2.5
p-value: 0.33ANCOVA
Secondary

ADHD Hyperactive/Impulsive Scale, Conners ADHD Scales

Parent rated hyperactive/impulsive ADHD symptoms, based on Diagnostic and Statistical Manual of Mental Disorders criteria, 4th edition.T-scores are reported. Higher scores indicate increased ADHD-related symptoms. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinADHD Hyperactive/Impulsive Scale, Conners ADHD ScalesBaseline65.5 T scoreStandard Deviation 14.2
LovastatinADHD Hyperactive/Impulsive Scale, Conners ADHD ScalesPost-treatment62.3 T scoreStandard Deviation 15.4
PlaceboADHD Hyperactive/Impulsive Scale, Conners ADHD ScalesBaseline62.9 T scoreStandard Deviation 15.6
PlaceboADHD Hyperactive/Impulsive Scale, Conners ADHD ScalesPost-treatment62.3 T scoreStandard Deviation 16.7
p-value: 0.37ANCOVA
Secondary

ADHD Inattentive Scale, Conners ADHD Scales

Parent rated inattentive ADHD symptoms, based on Diagnostic and Statistical Manual of Mental Disorders criteria, 4th edition. T-scores are reported. Higher scores indicate increased ADHD-related symptoms. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinADHD Inattentive Scale, Conners ADHD ScalesBaseline66.2 T scoreStandard Deviation 12.6
LovastatinADHD Inattentive Scale, Conners ADHD ScalesPost-treatment59.5 T scoreStandard Deviation 13.2
PlaceboADHD Inattentive Scale, Conners ADHD ScalesBaseline64.0 T scoreStandard Deviation 14.6
PlaceboADHD Inattentive Scale, Conners ADHD ScalesPost-treatment61.1 T scoreStandard Deviation 13.3
p-value: 0.09ANCOVA
Secondary

Behavior Rating Inventory of Executive Function Global Executive Composite

A parent-rated questionnaire of executive behaviour assessing behavioral regulation (inhibit, shift, emotional control) and metacognition (initiate, working memory, plan/organize, organization of materials, self-monitoring). T-scores for the Global Executive Composite (overall summary score) are reported. Higher scores indicate poorer executive behaviors.

Time frame: Baseline and Post-treatment (week 16)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinBehavior Rating Inventory of Executive Function Global Executive CompositeBaseline63.5 T scoreStandard Deviation 11.5
LovastatinBehavior Rating Inventory of Executive Function Global Executive CompositePost-treatment59.2 T scoreStandard Deviation 13.2
PlaceboBehavior Rating Inventory of Executive Function Global Executive CompositePost-treatment58.8 T scoreStandard Deviation 12.5
PlaceboBehavior Rating Inventory of Executive Function Global Executive CompositeBaseline61.4 T scoreStandard Deviation 11.9
p-value: 0.25ANCOVA
Secondary

Commission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)

A computerised measure of impulse control. Letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Commission errors represented the number of times a participant incorrectly responded to the non-target (letter 'X'). T-scores are reported, as generated by the test software. Higher scores indicate poorer performances.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinCommission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Baseline57.5 T scoreStandard Deviation 12.4
LovastatinCommission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Post-treatment58.8 T scoreStandard Deviation 16.6
PlaceboCommission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Baseline62.1 T scoreStandard Deviation 17.2
PlaceboCommission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Post-treatment64.1 T scoreStandard Deviation 18.4
p-value: 0.49ANCOVA
Secondary

Controlled Oral Word Association Test

A measure of verbal fluency. Participants were required to spontaneously produce as many words as they could, beginning with a designated letter in 60 seconds. Three letters were used. Higher scores represent better performances. Raw data are reported summing total words generated for all three letters. Scale does not have a maximum range.

Time frame: Baseline and Post-treatment (week 16)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinControlled Oral Word Association TestPost-treatment22.2 Total wordsStandard Deviation 9.1
LovastatinControlled Oral Word Association TestBaseline22.2 Total wordsStandard Deviation 8.9
PlaceboControlled Oral Word Association TestPost-treatment22.6 Total wordsStandard Deviation 8.9
PlaceboControlled Oral Word Association TestBaseline21.2 Total wordsStandard Deviation 8.6
p-value: 0.18ANCOVA
Secondary

Creature Counting (Test of Everyday Attention for Children)

Creature Counting is a measure of attentional control. Participants were required to count creatures from top of the page to the bottom, using arrows as cues to switch from counting up to counting down (and vice versa). There were seven testing trials. The outcome variable was the total number of correct trials (range 0-7). Higher scores represent better performances.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinCreature Counting (Test of Everyday Attention for Children)Baseline4.0 Scores on a scaleStandard Deviation 2.2
LovastatinCreature Counting (Test of Everyday Attention for Children)Post-treatment4.5 Scores on a scaleStandard Deviation 1.9
PlaceboCreature Counting (Test of Everyday Attention for Children)Post-treatment4.6 Scores on a scaleStandard Deviation 1.8
PlaceboCreature Counting (Test of Everyday Attention for Children)Baseline3.8 Scores on a scaleStandard Deviation 2.3
p-value: 0.37ANCOVA
Secondary

Internalizing Behaviors, Behavior Assessment System for Children Second Edition

A parent-reported questionnaire assessing internalizing behaviors of anxiety, depression and somatization. T-scores are reported. Higher scores indicate increased internalizing behaviors. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.

Time frame: Baseline and Post-treatment (week 16)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinInternalizing Behaviors, Behavior Assessment System for Children Second EditionBaseline55.2 T scoreStandard Deviation 12.6
LovastatinInternalizing Behaviors, Behavior Assessment System for Children Second EditionPost-treatment52.6 T scoreStandard Deviation 12.6
PlaceboInternalizing Behaviors, Behavior Assessment System for Children Second EditionBaseline53.8 T scoreStandard Deviation 11.8
PlaceboInternalizing Behaviors, Behavior Assessment System for Children Second EditionPost-treatment52.5 T scoreStandard Deviation 11.4
p-value: 0.5ANCOVA
Secondary

Internalizing Behaviors, Behavior Assessment System for Children Second Edition

A self-reported questionnaire assessing internalizing behaviors such as anxiety and depression. T-scores are reported. Higher scores indicate increased internalizing behaviors. A score below 60 is considered healthy, 61-65 a possible significant problem, and 66+ is considered a significant problem.

Time frame: Baseline and Post-treatment (week 16)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinInternalizing Behaviors, Behavior Assessment System for Children Second EditionPost-treatment47.9 T scoreStandard Deviation 10
LovastatinInternalizing Behaviors, Behavior Assessment System for Children Second EditionBaseline50.9 T scoreStandard Deviation 10.2
PlaceboInternalizing Behaviors, Behavior Assessment System for Children Second EditionBaseline51.2 T scoreStandard Deviation 8.7
PlaceboInternalizing Behaviors, Behavior Assessment System for Children Second EditionPost-treatment49.2 T scoreStandard Deviation 8.5
p-value: 0.33ANCOVA
Secondary

Judgement of Line Orientation Test

A test of visuospatial judgement. The test measured the participant's ability to match the angle and orientation of lines in space. There were 30 trial in total. Correct response in a trial was awarded one point (range 0-30). Higher scores represent better performances. Raw data are reported.

Time frame: Baseline and Post-treatment (week 16)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinJudgement of Line Orientation TestBaseline15.0 Total correct responsesStandard Deviation 6.6
LovastatinJudgement of Line Orientation TestPost-treatment17.2 Total correct responsesStandard Deviation 7
PlaceboJudgement of Line Orientation TestBaseline14.6 Total correct responsesStandard Deviation 5.7
PlaceboJudgement of Line Orientation TestPost-treatment16.7 Total correct responsesStandard Deviation 6.4
p-value: 0.88ANCOVA
Secondary

Object Assembly (WISC-III)

A measure of visuoperceptual organization. Participants were required to rebuild an item puzzle based on disassembled pieces. Age scaled scores are reported, which have a population mean of 10 and standard deviation of 3 (range 1-19). Higher scores indicate better performances.

Time frame: Baseline and Post-treatment (week 16)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinObject Assembly (WISC-III)Baseline6.6 Scores on a scaleStandard Deviation 3.1
LovastatinObject Assembly (WISC-III)Post-treatment7.8 Scores on a scaleStandard Deviation 3.6
PlaceboObject Assembly (WISC-III)Baseline6.9 Scores on a scaleStandard Deviation 3
PlaceboObject Assembly (WISC-III)Post-treatment7.5 Scores on a scaleStandard Deviation 3.3
p-value: 0.2ANCOVA
Secondary

Omission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)

A computerised measure of vigilance and concentration. Letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Omission errors represented the number of times a participant fails to respond to target letters (all other than 'X'). T-scores are reported, as generated by the test software. Higher scores indicate poorer performances.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinOmission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Baseline54.7 T scoreStandard Deviation 10.5
LovastatinOmission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Post-treatment54.2 T scoreStandard Deviation 10.5
PlaceboOmission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Baseline56.9 T scoreStandard Deviation 6.9
PlaceboOmission Errors (Conners Continuous Performance Test, Second Edition; CPT-II)Post-treatment55.5 T scoreStandard Deviation 7.4
p-value: 0.86ANCOVA
Secondary

Psychosocial Quality of Life PedsQL

Self-rated questionnaire of psychosocial Quality of Life (including emotional, social and school functioning). Summary scores are reported. Higher scores indicate higher quality of life (range 0-100).

Time frame: Baseline and Post-treatment (week 16)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinPsychosocial Quality of Life PedsQLPost-treatment62.6 Scores on a scaleStandard Deviation 16
LovastatinPsychosocial Quality of Life PedsQLBaseline67.2 Scores on a scaleStandard Deviation 17
PlaceboPsychosocial Quality of Life PedsQLBaseline70.0 Scores on a scaleStandard Deviation 18.1
PlaceboPsychosocial Quality of Life PedsQLPost-treatment67.3 Scores on a scaleStandard Deviation 17
p-value: 0.73ANCOVA
Secondary

Quality of Life Pediatric Quality of Life Inventory (PedsQL)

Parent-rated questionnaire of psychosocial Quality of Life (including emotional, social and school functioning). Summary scores are reported. Higher scores indicate increased increased quality of life (range 0-100).

Time frame: Baseline and Post-treatment (week 16)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinQuality of Life Pediatric Quality of Life Inventory (PedsQL)Baseline62.8 Scores on a scaleStandard Deviation 15.7
LovastatinQuality of Life Pediatric Quality of Life Inventory (PedsQL)Post-treatment69.2 Scores on a scaleStandard Deviation 16
PlaceboQuality of Life Pediatric Quality of Life Inventory (PedsQL)Baseline64.6 Scores on a scaleStandard Deviation 18.1
PlaceboQuality of Life Pediatric Quality of Life Inventory (PedsQL)Post-treatment68.1 Scores on a scaleStandard Deviation 16.6
p-value: 0.3ANCOVA
Secondary

Sky Search DT (Test of Everyday Attention for Children)

Sky Search DT is a test of divided attention. Children completed a parallel version of the Sky Search subtest while at the same time, silently counted the number of tones in a similar way to the Score! subtest. Higher scores represent poorer performance. Raw data are reported. Scale does not have a maximum range.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinSky Search DT (Test of Everyday Attention for Children)Baseline9.9 Scores on a scaleStandard Deviation 15.5
LovastatinSky Search DT (Test of Everyday Attention for Children)Post-treatment7.0 Scores on a scaleStandard Deviation 15.6
PlaceboSky Search DT (Test of Everyday Attention for Children)Baseline9.6 Scores on a scaleStandard Deviation 18.6
PlaceboSky Search DT (Test of Everyday Attention for Children)Post-treatment6.6 Scores on a scaleStandard Deviation 11.6
p-value: 0.9ANCOVA
Secondary

Sky Search (Test of Everyday Attention for Children)

Sky Search is a measure of selective visual attention. Participants were presented with a A3 sheet with target stimuli (spaceships in identical pairs) randomly distributed among many distractors (spaceships in non-identical pairs). They were required to circle as many of the targets as possible as quickly as possible. The outcome measure (attention score), was a timing score reflecting the average time taken per target found. Higher scores represent poorer performance. Raw data are reported. Scale does not have a maximum range.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinSky Search (Test of Everyday Attention for Children)Baseline4.4 Scores on a scaleStandard Deviation 1.7
LovastatinSky Search (Test of Everyday Attention for Children)Post-treatment4.0 Scores on a scaleStandard Deviation 2
PlaceboSky Search (Test of Everyday Attention for Children)Baseline5.0 Scores on a scaleStandard Deviation 2.1
PlaceboSky Search (Test of Everyday Attention for Children)Post-treatment4.4 Scores on a scaleStandard Deviation 2.1
p-value: 0.99ANCOVA
Secondary

Spatial Working Memory (Cambridge Neuropsychological Test Automated Battery)

A computerized measure of spatial working memory. This task assessed the participant's ability to retain spatial information and to manipulate remembered items in working memory. In this test, participants were shown an array of boxes on a computer screen and they were required to search through the boxes for hidden tokens. One box at a time was touched until a blue token was found inside. Participants then commenced a new search for the next token. The key instruction was that, once a token had been located, that box would not be used again to hide another token. Unit of measure was between search errors, determined by the number of boxes a participant reopens in which a token had previously been found. Higher score indicated poorer performance. Scale does not have a maximum range.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinSpatial Working Memory (Cambridge Neuropsychological Test Automated Battery)Baseline47.0 ErrorsStandard Deviation 15.9
LovastatinSpatial Working Memory (Cambridge Neuropsychological Test Automated Battery)Post-treatment40.4 ErrorsStandard Deviation 17.2
PlaceboSpatial Working Memory (Cambridge Neuropsychological Test Automated Battery)Post-treatment41.6 ErrorsStandard Deviation 17
PlaceboSpatial Working Memory (Cambridge Neuropsychological Test Automated Battery)Baseline47.9 ErrorsStandard Deviation 16.2
p-value: 0.86ANCOVA
Secondary

Stockings of Cambridge (Cambridge Neuropsychological Test Automated Battery) Automated Battery).

A computerized measure of spatial planning based on the Tower of London test. It required participants to move balls in a lower display to match a pattern shown in the upper display in a certain number of moves. More specifically, the participant was shown two displays containing three coloured balls. The displays were presented in such a way that they could be perceived as stacks of coloured balls held in socks suspended from a beam. The test administrator first demonstrated to the participant how to move the balls in the lower display to copy the pattern in the upper display and completed one demonstration problem, where the solution required one move. The participant then completed problems that increased in difficulty, from one through to five move problems. The unit of measure was the mean number of moves taken to complete a problem that could not be completed in less than five moves. The higher the score, the poorer the performance (range 5-12).

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinStockings of Cambridge (Cambridge Neuropsychological Test Automated Battery) Automated Battery).Baseline7.9 MovesStandard Deviation 1.4
LovastatinStockings of Cambridge (Cambridge Neuropsychological Test Automated Battery) Automated Battery).Post-treatment7.3 MovesStandard Deviation 1.4
PlaceboStockings of Cambridge (Cambridge Neuropsychological Test Automated Battery) Automated Battery).Baseline8.0 MovesStandard Deviation 1.3
PlaceboStockings of Cambridge (Cambridge Neuropsychological Test Automated Battery) Automated Battery).Post-treatment7.9 MovesStandard Deviation 1.4
p-value: 0.04ANCOVA
Secondary

Stop Signal Task (Cambridge Neuropsychological Test Automated Battery)

A computerized measure of inhibitory control. The participant quickly responded to an arrow stimulus by pressing one of two buttons (left or right), depending on the direction in which the arrow pointed on the screen. If an audio tone is present, the subject was supposed to withhold the response. The difficulty of the task was manipulated by altering the delay before a stop signal (auditory tone) was presented, known as the stop signal delay. The outcome from this measure was stop signal reaction time (last half of test), which was computed by subtracting the mean stop signal delay at which the participant was able to stop on 50% of trials from the mean reaction time on go trials. Poorer response inhibition was reflected by a larger stop signal reaction time. Scale does not have a maximum range.

Time frame: Baseline and Post-treatment (16 weeks)

Population: Intention to treat using the modified intention-to-treat population (defined as all subjects that had baseline data). Missing post-treatment values were imputed using linear regression with age, sex and baseline values used as predictors (20 imputations).

ArmMeasureGroupValue (MEAN)Dispersion
LovastatinStop Signal Task (Cambridge Neuropsychological Test Automated Battery)Baseline264.7 MillisecondsStandard Deviation 98.7
LovastatinStop Signal Task (Cambridge Neuropsychological Test Automated Battery)Post-treatment227.2 MillisecondsStandard Deviation 87.2
PlaceboStop Signal Task (Cambridge Neuropsychological Test Automated Battery)Baseline237.2 MillisecondsStandard Deviation 75.9
PlaceboStop Signal Task (Cambridge Neuropsychological Test Automated Battery)Post-treatment227.0 MillisecondsStandard Deviation 93.7
p-value: 0.33ANCOVA

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026